Aridis Pharmaceuticals Pink Sheet Forecast - Naive Prediction
| ARDS Stock | USD 0.0002 0.0001 33.33% |
The Naive Prediction forecasted value of Aridis Pharmaceuticals on the next trading day is expected to be -0 with a mean absolute deviation of 0.0007 and the sum of the absolute errors of 0.04. Aridis Pink Sheet Forecast is based on your current time horizon.
At this time the relative strength index (rsi) of Aridis Pharmaceuticals' share price is below 20 . This suggests that the pink sheet is significantly oversold. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards. Momentum 0
Sell Peaked
Oversold | Overbought |
Using Aridis Pharmaceuticals hype-based prediction, you can estimate the value of Aridis Pharmaceuticals from the perspective of Aridis Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors.
The Naive Prediction forecasted value of Aridis Pharmaceuticals on the next trading day is expected to be -0 with a mean absolute deviation of 0.0007 and the sum of the absolute errors of 0.04. Aridis Pharmaceuticals after-hype prediction price | USD 2.97E-4 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as pink sheet price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Aridis |
Aridis Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Aridis price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Aridis using various technical indicators. When you analyze Aridis charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Aridis Pharmaceuticals Naive Prediction Price Forecast For the 24th of January
Given 90 days horizon, the Naive Prediction forecasted value of Aridis Pharmaceuticals on the next trading day is expected to be -0 with a mean absolute deviation of 0.0007, mean absolute percentage error of 0.00000067, and the sum of the absolute errors of 0.04.Please note that although there have been many attempts to predict Aridis Pink Sheet prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Aridis Pharmaceuticals' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Aridis Pharmaceuticals Pink Sheet Forecast Pattern
| Backtest Aridis Pharmaceuticals | Aridis Pharmaceuticals Price Prediction | Buy or Sell Advice |
Aridis Pharmaceuticals Forecasted Value
In the context of forecasting Aridis Pharmaceuticals' Pink Sheet value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Aridis Pharmaceuticals' downside and upside margins for the forecasting period are 0.000002 and 316.16, respectively. We have considered Aridis Pharmaceuticals' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Aridis Pharmaceuticals pink sheet data series using in forecasting. Note that when a statistical model is used to represent Aridis Pharmaceuticals pink sheet, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 103.8967 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 7.0E-4 |
| MAPE | Mean absolute percentage error | 1.7828 |
| SAE | Sum of the absolute errors | 0.0436 |
Predictive Modules for Aridis Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Aridis Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Aridis Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Aridis Pharmaceuticals After-Hype Price Prediction Density Analysis
As far as predicting the price of Aridis Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Aridis Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Pink Sheet prices, such as prices of Aridis Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Aridis Pharmaceuticals Estimiated After-Hype Price Volatility
In the context of predicting Aridis Pharmaceuticals' pink sheet value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Aridis Pharmaceuticals' historical news coverage. Aridis Pharmaceuticals' after-hype downside and upside margins for the prediction period are 0.00 and 50.02, respectively. We have considered Aridis Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Aridis Pharmaceuticals is out of control at this time. Analysis and calculation of next after-hype price of Aridis Pharmaceuticals is based on 3 months time horizon.
Aridis Pharmaceuticals Pink Sheet Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Aridis Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aridis Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Pink Sheet price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Aridis Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
110.23 | 316.16 | 0.00 | 0.00 | 0 Events / Month | 1 Events / Month | In 5 to 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
0.0002 | 0.0003 | 0.90 |
|
Aridis Pharmaceuticals Hype Timeline
Aridis Pharmaceuticals is presently traded for 0.0002. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Aridis is forecasted to decline in value after the next headline, with the price expected to drop to 2.97E-4. The average volatility of media hype impact on the company price is insignificant. The price decrease on the next news is expected to be -0.9%, whereas the daily expected return is presently at 110.23%. The volatility of related hype on Aridis Pharmaceuticals is about 0.0%, with the expected price after the next announcement by competition of 0.00. About 32.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.15. Aridis Pharmaceuticals had not issued any dividends in recent years. Given the investment horizon of 90 days the next forecasted press release will be in 5 to 10 days. Check out Historical Fundamental Analysis of Aridis Pharmaceuticals to cross-verify your projections.Aridis Pharmaceuticals Related Hype Analysis
Having access to credible news sources related to Aridis Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Aridis Pharmaceuticals' future price movements. Getting to know how Aridis Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Aridis Pharmaceuticals may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| INFIQ | Infinity Pharmaceuticals | 0.00 | 8 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EVLO | Evelo Biosciences | 0.00 | 0 per month | 0.00 | 0.11 | 0.00 | (20.00) | 400.00 | |
| HSTC | HST Global | 0.00 | 0 per month | 0.00 | 0.18 | 0.00 | 0.00 | 4,954 | |
| LIFS | Life Stem Genetics | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| TRVN | Trevena | 0.00 | 6 per month | 0.00 | 0.11 | 0.00 | 0.00 | 1,000.00 | |
| AFIB | Acutus Medical | 0.00 | 0 per month | 0.00 | 0.17 | 100.00 | (70.00) | 2,997 | |
| BTAX | Biostax Corp | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| STAB | Statera Biopharma | 0.00 | 0 per month | 21.51 | 0.19 | 100.00 | (66.67) | 275.00 | |
| TCLIF | Theraclion SA | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| ICCT | iCoreConnect Common stock | 0.00 | 0 per month | 31.71 | 0.16 | 100.00 | (72.73) | 522.73 |
Other Forecasting Options for Aridis Pharmaceuticals
For every potential investor in Aridis, whether a beginner or expert, Aridis Pharmaceuticals' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Aridis Pink Sheet price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Aridis. Basic forecasting techniques help filter out the noise by identifying Aridis Pharmaceuticals' price trends.Aridis Pharmaceuticals Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aridis Pharmaceuticals pink sheet to make a market-neutral strategy. Peer analysis of Aridis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aridis Pharmaceuticals by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Aridis Pharmaceuticals Market Strength Events
Market strength indicators help investors to evaluate how Aridis Pharmaceuticals pink sheet reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Aridis Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Aridis Pharmaceuticals pink sheet market strength indicators, traders can identify Aridis Pharmaceuticals entry and exit signals to maximize returns.
| Accumulation Distribution | 7069.33 | |||
| Daily Balance Of Power | (1.00) | |||
| Rate Of Daily Change | 0.67 | |||
| Day Median Price | 3.0E-4 | |||
| Day Typical Price | 2.0E-4 | |||
| Price Action Indicator | (0.0001) | |||
| Period Momentum Indicator | (0.0001) |
Aridis Pharmaceuticals Risk Indicators
The analysis of Aridis Pharmaceuticals' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Aridis Pharmaceuticals' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting aridis pink sheet prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 208.59 | |||
| Semi Deviation | 37.33 | |||
| Standard Deviation | 314.44 | |||
| Variance | 98872.65 | |||
| Downside Variance | 7401.32 | |||
| Semi Variance | 1393.87 | |||
| Expected Short fall | (659.24) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Aridis Pharmaceuticals
The number of cover stories for Aridis Pharmaceuticals depends on current market conditions and Aridis Pharmaceuticals' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Aridis Pharmaceuticals is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Aridis Pharmaceuticals' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Aridis Pharmaceuticals Short Properties
Aridis Pharmaceuticals' future price predictability will typically decrease when Aridis Pharmaceuticals' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Aridis Pharmaceuticals often depends not only on the future outlook of the potential Aridis Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Aridis Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 27 M | |
| Cash And Short Term Investments | 4.9 M |
Additional Tools for Aridis Pink Sheet Analysis
When running Aridis Pharmaceuticals' price analysis, check to measure Aridis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aridis Pharmaceuticals is operating at the current time. Most of Aridis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aridis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aridis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aridis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.